Jörn M. Schattenberg

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Chris Estes, Quentin M. Anstee, M. Arias et al. · Journal of Hepatology · 2018 · 2K citations · Full text

Medicine, Health Sciences, Epidemiologic Methods +16

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · New England Journal of Medicine · 2024 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis

Stuart McPherson, Timothy Hardy, Jean‐François Dufour et al. · The American Journal of Gastroenterology · 2016 · 891 citations · Full text

Medicine, Internal Medicine, Pathology +17